Neoleukin.png
Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference
May 26, 2021 08:00 ET | Neoleukin Therapeutics, Inc.
SEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin.png
Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update
May 12, 2021 08:00 ET | Neoleukin Therapeutics, Inc.
- Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 - - Appointed Priti Patel, M.D., as Chief Medical Officer - - Cash and cash equivalents of $178.4 million expected...
Neoleukin.png
Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial
May 05, 2021 08:00 ET | Neoleukin Therapeutics, Inc.
SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin.png
Neoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference
May 04, 2021 08:00 ET | Neoleukin Therapeutics, Inc.
SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin.png
Neoleukin Therapeutics Announces Appointment of Priti Patel, M.D., M.S., as Chief Medical Officer
May 03, 2021 08:00 ET | Neoleukin Therapeutics, Inc.
SEATTLE, May 03, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin.png
Neoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United States
April 26, 2021 07:00 ET | Neoleukin Therapeutics, Inc.
SEATTLE, April 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin.png
Neoleukin Therapeutics Announces Year End 2020 Financial Results
March 25, 2021 16:00 ET | Neoleukin Therapeutics, Inc.
- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 - - Cash and cash equivalents of $192.6 million expected to fund operations into 2023 - - Company to host Conference Call Today,...
Neoleukin.png
Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021
March 18, 2021 08:00 ET | Neoleukin Therapeutics, Inc.
SEATTLE, March 18, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin.png
Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
March 02, 2021 08:00 ET | Neoleukin Therapeutics, Inc.
SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin.png
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
February 05, 2021 08:00 ET | Neoleukin Therapeutics, Inc.
SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...